Curevo Inc. is a biotechnology company focused on developing vaccines for infectious diseases. Its lead candidate, amezosvatein, is an adjuvanted subunit vaccine targeting shingles in adults. In a Phase 2 trial, it demonstrated comparable immune responses to the standard of care while showing improved tolerability, with reduced rates of activity-limiting fatigue, chills, and injection-site reactions.
Official website: curevovaccine.com
To provide comprehensive coverage, we aggregate data and news under the name Curevo, encompassing the following company names, divisions, and related entities:
Curevo Vaccine.
This list encompasses current and former names, alternate names, and key divisions associated with Curevo, ensuring you can easily find all relevant information under a single, unified profile.
